Search clinical trials for: Faster Insulin Aspart (Fiasp®)

Total 1195 results

Mountain Diabetes and Endocrine Center

Unknown

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus (PLATEAU)

Type 1 Diabetes Mellitus

United States
Rigshospitalet, Denmark

Completed

Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes

Diabetes Mellitus | Pregnancy Complications

Denmark
Medical University of Warsaw

Not yet recruiting

Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?

Diabetes Mellitus, Type 1 | Diabetes type1
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device (GoBolus)

Diabetes | Diabetes Mellitus, Type 1 Diabetes

Germany
Novo Nordisk A/S

Completed

An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes (SAFE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Philippines
University of Aarhus
Novo Nordisk A/S

Completed

A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin

Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Macedonia, The Former Yugoslav Republic of
Adocia

Completed

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Type1 Diabetes Mellitus

Germany
University Hospital, Strasbourg, France

Recruiting

Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes (MIRE)

Cystic Fibrosis-related Diabetes

France
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Boston Medical Center
Novo Nordisk A/S

Completed

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (In-FI)

Type 2 Diabetes Treated With Insulin

United States
Eli Lilly and Company

Completed

A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
University of Aarhus

Completed

Pharmacokinetics of IAsp Following CSII in Patients With T1DM

Type 1 Diabetes Mellitus

Denmark
Novo Nordisk A/S

Completed

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin (Mix2Mix)

Diabetes Mellitus, Type 2 | Diabetes

Belgium, Luxembourg
Texas Diabetes & Endocrinology, P.A.

Completed

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2 | Diabetes

India
Stanford University
Medtronic

Completed

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Former Serbia and Montenegro
Novo Nordisk A/S

Withdrawn

A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria (B Simple)

Diabetes Mellitus, Type 2

Algeria
Novo Nordisk A/S

Completed

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes (IMPROVE™)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, China, India, Iran, Islamic Republic of, Korea, Republic of, Russian Federation, Poland, Japan, Italy, Canada, Greece
Jesús Moreno Fernández
University of Castilla-La Mancha

Completed

Faster Aspart on Insulin-pump Treated T1DM Patients (realFACI)

Type 1 Diabetes

Spain
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs (IMPROVE)

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects

Clamp Study

Russian Federation
Novo Nordisk A/S

Completed

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, Sweden
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

Diabetes Mellitus, Type 2 | Diabetes

Tunisia
University of Ljubljana, Faculty of Medicine
Medical University of Graz Department of Pediatrics and Adolescent Medicine... and other collaborators

Completed

Fast Advanced Closed-Loop Therapy (FACT)

Type 1 Diabetes

Austria, Slovenia
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2 | Diabetes

Israel
Novo Nordisk A/S

Completed

Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Romania
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Indonesia
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Saudi Arabia
Novo Nordisk A/S

Completed

Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Diabetes Mellitus, Type 2 | Diabetes

Hungary
Novo Nordisk A/S

Completed

Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes (IMPROVE Life)

Diabetes Mellitus, Type 2 | Diabetes

India
Novo Nordisk A/S

Completed

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin (COMMIT)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia
Novo Nordisk A/S

Completed

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin

Diabetes Mellitus, Type 2 | Diabetes

Czech Republic
Novo Nordisk A/S

Completed

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes (onset® 4)

Diabetes | Diabetes Mellitus, Type 1

United States, Germany
Novo Nordisk A/S

Completed

An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment (Start)

Diabetes Mellitus, Type 2 | Diabetes

Finland
Novo Nordisk A/S

Completed

Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia

Diabetes Mellitus, Type 2 | Diabetes

Macedonia, The Former Yugoslav Republic of
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes (INTENSIV)

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Novo Nordisk A/S

Completed

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Completed

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Aristotle University Of Thessaloniki

Unknown

Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor

Type 1 Diabetes

Greece
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes (EFFECTIVE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Former Serbia and Montenegro

3

Subscribe